Diagnoses of prostatic carcinoma (PC) have increased with widespread screening. While the use of a-methylacyl coA racemase and high molecular weight cytokeratins have aided in distinguishing benign mimics from malignancy, their sensitivity and specificity are limited. We studied 6C4, a monoclonal antibody to glutamate receptor 2, an excitatory amino acid receptor subunit distributed throughout the central nervous system, on benign prostatic epithelium, high-grade prostatic intraepithelial neoplasia, and PC. Ten cases with post-atrophic or adenosis-like prostate glands were also stained with prostatic intraepithelial neoplasia 4, an immunostain cocktail against a-methylacyl coA racemase, p63, and high molecular weight cytokeratin, in parallel with 6C4. Immunoreactivity for 6C4 was graded as negative (0% to 10%), +1 (11%% to 50%), and +2 (>50%). Malignant epithelium was classified by Gleason patterns. Gleason patterns 4 and 5 were subdivided into cribriform or noncribriform type. Its utility in distinguishing postatrophic or adenosis-like glands from prostate cancer, both of which show absence of basal cells on prostatic intraepithelial neoplasia 4 immunostain, was also investigated. Our results revealed a statistically significant difference in staining of benign secretory prostatic epithelium, high-grade prostatic intraepithelial neoplasia, and low Gleason pattern carcinomas. The results also showed 6C4 is a sensitive marker in separating basal cell negative postatrophic or adenosis-like glands from prostate carcinoma. In addition, there was a statistically significant difference between staining of cribriform versus noncribriform Gleason pattern 4 and 5 carcinomas. A limited number of lymph node metastases from cribriform and noncribriform carcinomas were studied, and they stained the same as the primary tumor in the majority of cases. In conclusion, our preliminary data demonstrated potential utility of 6C4 in the pathologic evaluation of PC.
W ith the increasing public awareness of prostatic carcinoma (PC), the widespread use of prostatespecific antigen serum levels as a screening modality, and transrectal ultrasonography to target specific lesions, prostatic needle core biopsies have resulted in increased clinical detection of cancer. Pathologists are evaluating increased quantities of prostatic needle core biopsies with fewer and smaller foci of PC. Immunohistochemistry has emerged as a valuable aid in differentiating PC from its benign mimics. Although there are increased diagnoses of prostate cancer, the majority of tumors will have indolent behavior. We studied the immunohistochemical staining of 6C4, a monoclonal antibody to glutamate receptor 2 (GluR2) on prostatic specimens. GluR2 is an excitatory amino acid receptor subunit distributed throughout the central nervous system with sites including the hippocampus, cortex, and spinal cord. [1] [2] [3] GluR2 is critical for the regulation of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor properties and synaptic plasticity; however, its exact mechanisms are unclear. 4 In this study, we explore the utility of 6C4 in the evalution of prostate carcinoma.
MATERIALS AND METHODS

Tissue Samples
Specimens for this study consisted solely of tissue processed at the Mount Sinai Hospital pathology department. We studied 113 prostate carcinomas: 77% were prostatic needle core biopsies and 23% were radical prostatectomy specimens. Exclusion criteria included consult cases and cases with only benign tissue.
Analysis With 6C4
After deparaffinization and rehydration, slides were treated with 3% hydrogen peroxide to eliminate endogenous peroxidase activity, then processed for antigen retrieval with 10 mM citrate buffer pH 6.0 using a pressure cooker (Pascal; Dako Cytomation) for 4 minutes at 1251C, followed by slow cooling. All sections were rinsed with phosphate buffered saline (137 mM NaCl, 2.7 mM potassium chloride, 4.2 mM sodium phosphate, and 1.5 mM potassium phosphate) briefly. The sections were given a 2-hour incubation with glutamate receptor subunit protein (GluR2) antibody (6C4; monoclonal), a gift of Dr John H. Morrison (Department of Neuroscience, the Mount Sinai School of Medicine), at 0.8 mg/ mL diluted in 1% bovine serum albumin and 5% normal goat serum in phosphate buffered saline at room temperture. UltraVision LP Detection System HRP Polymer and DAB Plus Chromogen (Thermo Fisher Scientific) was used as secondary antibody according to their manufacturer protocol. Immunoreactivity was visualized with diaminobenzadine, counterstained with hematoxylin, dehydrated, and mounted.
Two pathologists evaluated the immunohistochemical staining in each Gleason pattern of each PC without knowledge at analysis of diagnosed Gleason pattern. Staining was estimated as a percentage for each Gleason pattern and specific morphologic variants. Staining was grouped as negative (0% to 10%), +1 (11% to 50%), and +2 (>50%). Cytoplasmic and membranous staining was considered positive immunostaining. Slides with differing estimations between the 2 pathologists were re-reviewed, and differences were resolved with consensus interpretation.
Immunohistochemical Staining With Prostatic Intraepithelial Neoplasia 4 (PIN4) Immunohistochemistry Cocktail
Ten cases that contained postatrophic or adenosislike prostate glands were also stained with PIN4, in parallel with 6C4. The PIN4 cocktail consists of a polyclonal antibody against p504S (Biocare Medical, Concord, CT) in a ready to use preparation in addition to a basal cell cocktail. The basal cell cocktail consists of a high molecular weight anticytokeratin antibody (34bE12) and an anti-p63 antibody (4A4) (Ventana Medical Systems, Tucson, AZ) in a ready to use preparation.
Statistical Analysis
The differences between groups were evaluated by the Fisher exact test. A P value of <0.05 was considered statistically significant.
RESULTS
A total of 113 PCs were reviewed for 6C4 staining. Benign prostatic epithelium was also present in each case. All benign prostatic secretory epithelium showed immunoreactivity of virtually 100% for 6C4 antibody (Fig. 1 ). There were 35 high-grade prostatic intraepithelial neoplasias (HGPINs), all of which showed negative immunoreactivity ( Fig. 2 ). Of the 59 Gleason pattern 3 prostate carcinomas, 57 showed negative immunoreactivity ( Fig. 3 ), 1 showed +1 immunoreactivity, and 1 showed +2 immunoreactivity. Of the 41 noncribriform Gleason pattern 4 carcinomas, 11 showed negative immunoreactivity, 19 showed +1 immunoreactivity, and 21 showed +2 immunoreactivity ( Fig. 4 ). Among the 10 Gleason pattern 5 noncribriform carcinoma, 4 had negative immunoreactivity, none had +1 immunoreactivity, and 6 had +2 immunoreactivity (Fig. 4) . Cribriform variant of Gleason pattern 4 carcinoma was identified in 45 carcinomas, 43 of which showed negative immunoreactivity ( Fig. 5 ), 2 which had +1 immunoreactivity, and none with +2 immunoreactivity. Gleason pattern 5 cribriform variant was identified in 4 carcinomas, 100% of which had negative immunoreactivity (Fig. 6 ). The immunoreactivity results of benign, HGPIN, cribriform, and noncribriform PC are summarized in Table 1 . Two carcinomas had signet ring cell features. Both of these areas of signet ring features showed negative immunoreactivity. Also studied were 8 PCs metastatic to lymph nodes. These metastases followed the trend of the primary carcinoma staining patterns. Six of 8 metastases had areas of cribriform carcinoma, which has negative immunoreactivity. Five of 8 metastases had Gleason pattern 5 carcinoma. Of the 5 metastases, 2 had negative immunoreactivity and 3 had +2 immunoreactivity.
The postatrophic or adenosis-like glands in the 10 cases stained with PIN4 immunostain cocktail in parallel with 6C4 are shown in Figure 7 . In brief, postatrophic and adenosis-like glands with absence of basal cells on PIN4 immunostain displayed strongly positive reactivity with 6C4, supporting/confirming benignity.
DISCUSSION
Immunostaining in difficult cases has been used to distinguish benign from malignant prostate glands. A mainstay has been basal cell-associated markers including high molecular weight cytokeratin 34bE12 and p63. Although the absence of immunoreactivity supports carcinoma, benign diagnostic pitfalls that can have weak immunoreactivity include atrophy, atypical adenomatous hyperplasia, postatrophic hyperplasia, nephrogenic adenoma, and mesonephric glandular hyperplasia. [5] [6] [7] To increase diagnostic accuracy, basal cell-associated markers are often used in conjunction with a-methylacyl coA racemase (AMACR), which is positive in about 80% of PCs and HGPIN. 8 The positivity has its limitations in diagnosing PC. AMACR may lack immunoreactivity in up to 30% of each of the following carcinoma variants: atrophic, foamy gland, and pseudohyperplastic. 9 AMACR may also be positive in benign prostatic secretory epithelium with results of up to 21% of benign prostatic epithelium staining positively for AMACR. 8, [10] [11] [12] In this study, strong immunopositivity for 6C4 was present in virtually 100% of benign prostatic epithelium whereas HGPIN and the large majority (97%) of lowgrade invasive prostatic adenocarcinoma did not show any immunoreactivity.
The challenge urologic pathologists frequently face, particularly in biopsy specimens, is distinguishing benign glands from minute foci of prostatic cancer. It is not uncommon to see postatrophic and adenosis-like prostatic glands present with cytological atypia and negative immunostain for basal cells by high molecular weight cytokeratin and p63, which pose a diagnostic difficulty and might produce an ambiguous diagnosis. As shown in this study, the uniform positivity in benign glands, including postatrophic and adenosis-type glands, readily separated them from prostate cancer with low Gleason score, which are 6C4-negative, although both showed basal cell negativity in PIN4 immunostain. Therefore, 6C4 has a potential value in improving the accuracy of prostate cancer diagnosis, particularly in a subset of prostate biopsy specimens.
In addition, as demonstrated in the table, there is a statistically significant difference in the staining pattern between cribriform and noncribriform prostatic adenocarcinomas. Although cribriform carcinomas lost immunoreactivity, noncribriform pattern adenocarcinoma retained immunoreactivity. Rubin et al 13 found carcinomas with cribriform histology tend to present at a more advanced tumor stage than noncribriform carcinoma and have higher tumor volume. In this study, of the cribriform carcinomas with known stage information, 81% of cribriform carcinomas presented at stage pT3 and 19% of cribriform carcinomas presented at pT2. It is possible that the loss of immunoreactivity in cribriform carcinoma may represent a genetic aberration. Thus, there may be a genotypicphenotyic correlation in cribriform pattern PC that lack of 6C4 reactivity potentially reflects.
Loss of 6C4 immunoreactivity was also found in signet ring cell PC. Reviews of the literature on this variant have revealed that the prognosis of signet ring cell adenocarcinomas is comparable with high-grade adenocarcinomas. 14, 15 Future studies are needed to assess a correlation between these staining patterns and clinical follow-up. Also under current investigation are the potential uses of 6C4 for the evaluation of carcinomas of non-prostatic origin. The present study does not determine whether 6C4 reacts with GluR2 or with another cross-reacting antigen. In conclusion, 6C4 is a potentially diagnostically useful immunohistochemical marker in improving diagnostic accuracy, particularly in distinguishing PC from benign diagnostic pitfalls. In terms of its prognostic value, further assessment is warranted.
